Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Michael, Graeber"'
Publikováno v:
Journal of Clinical Pharmacology
Trifarotene is a new drug with retinoic acid receptor activity and selectivity for retinoic acid receptor‐γ. The reported studies aimed at assessing the clinical pharmacology and safety of trifarotene. The clinical pharmacology of topical trifarot
Autor:
Lajos Kemény, Fran E Cook-Bolden, Ulrike Blume-Peytavi, Michael Graeber, Phoebe Rich, Faiz Ahmad, Joseph F. Fowler, Zoe Diana Draelos, Lawrence F. Eichenfield, Alessandra B Alió Saenz, Thomas Dirschka, Emil Tanghetti
Publikováno v:
Journal of the European Academy of Dermatology and Venereology
Author(s): Blume-Peytavi, U; Fowler, J; Kemeny, L; Draelos, Z; Cook-Bolden, F; Dirschka, T; Eichenfield, L; Graeber, M; Ahmad, F; Alio Saenz, A; Rich, P; Tanghetti, E | Abstract: BackgroundTreatment for both facial and truncal acne has not sufficient
Autor:
Lawrence F. Eichenfield, Jonathan S. Weiss, Faiz Ahmad, Emil Tanghetti, James Q Del Rosso, Jerry Tan, Alessandra B Alió Saenz, Michael Graeber, Linda Stein Gold, Fran E Cook-Bolden
Publikováno v:
Journal of the American Academy of Dermatology. 83:AB14
Autor:
Charles Lynde, Faiz Ahmad, Diane Thiboutot, Jonathan S. Weiss, Georg Popp, James Q Del Rosso, Lawrence Charles Parish, Nestor Sanchez Colon, Alessandra Alió Saenz, Ulrike Blume-Peytavi, Jerry Tan, Jolanta Weglovska, Michael Graeber, Linda Stein Gold, Sandra Marchese Johnson, Dagmara Witkowska, Melinda Gooderham
Publikováno v:
Journal of the American Academy of Dermatology. 80(6)
Background Acne vulgaris often affects the face, shoulders, chest, and back, but treatment of nonfacial acne has not been rigorously studied. Objectives Assess the safety and efficacy of trifarotene 50 μg/g cream, a novel topical retinoid, in modera
Publikováno v:
Sensors and Actuators A: Physical. 77:98-105
A new technology for fluidic microsystems has been developed at Rostock University. This new technology is based on the manufacturing principles of printed circuit boards (PCB). The same manufacturing steps closely connect fluidic and electric compon
Autor:
Ronan Bouer, Jean-Paul Chappuis, Francois Rony, Jean Jacovella, Michel Poncet, Khaled Benkali, Marie-Helene Peirone, Nathalie Wagner, Stéphane Delage, Michael Graeber
Publikováno v:
World Journal of Dermatology. 5:57
Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face
Autor:
Lawrence E, Eichenfield, Joseph L, Jorizzo, Thomas, Dirschka, Amy Forman, Taub, Charles, Lynde, Michael, Graeber, Nabil, Kerrouche
Publikováno v:
Journal of drugs in dermatology : JDD. 9(11)
Acne vulgaris is a common disease in adolescents, and early treatment may minimize its physical and psychological effects. A fixed-dose combination gel of adapalene 0.1% and benzoyl peroxide 2.5% (adapalene-BPO) is efficacious and safe in the treatme
Autor:
Lawrence F, Eichenfield, Michael, Jarratt, Joel, Schlessinger, Steven, Kempers, Vasant, Manna, Joyce, Hwa, Yin, Liu, Michael, Graeber, Derek, Woolner
Publikováno v:
Journal of drugs in dermatology : JDD. 9(6)
Acne vulgaris is a common chronic skin disease affecting roughly 15 percent of the general population and up to 85 percent of adolescents and young adults. Adapalene, a synthetic naphthoic acid derivative with retinoid activity, has demonstrated good
Autor:
Linda Stein, Gold, Jerry, Tan, Alma, Cruz-Santana, Kim, Papp, Yves, Poulin, Joel, Schlessinger, Judi, Gidner, Yin, Liu, Michael, Graeber
Publikováno v:
Cutis. 84(2)
A fixed-dose combination gel with adapalene 0.1% and benzoyl peroxide (BPO) 2.5% recently has been developed for the treatment of acne vulgaris. In this multicenter, randomized, double-blind, parallel-group, active- and vehicle-controlled study condu
Publikováno v:
Journal of drugs in dermatology : JDD. 7
The efficacy and safety of adapalene 0.1% gel in the treatment of acne vulgaris has been demonstrated in multiple controlled clinical trials. A higher concentration formulation, adapalene 0.3% gel, has been developed to provide a broader range of tre